Entry into the Cerebrovascular Market with Vascular Embolization Coils

「Sales related to cerebrovascular products amounted to ¥829 million (up 47.3% year on year).」

「Neurovascular revenue was ¥2,661 million, up 44.5% year on year. Differentiation through marketing initiatives highlighting the product's characteristics substantially expanded the market presence of the thrombectomy catheter. Embolization coil sales remained strong as the company developed new sales channels, including radiology, beyond its traditional neurovascular and abdominal markets. The number of facilities adopting the stent retriever also increased steadily, contributing to revenue growth.」

「Sales related to cerebrovascular products amounted to ¥2,661 million (up 44.5% year on year).」

「Neurovascular revenue was ¥1,187 million, up 48.4% year on year. A newly introduced model of the thrombectomy catheter for peripheral vessels significantly drove sales. The stent retriever, which was fully launched from the third quarter of the previous fiscal year, also got off to a stable start.」

「Neurovascular revenue was ¥800 million, up 126.3% year on year, setting a new record for a first-half period. The company also began selling stent retrievers as a new product, which began contributing to revenue during the current interim consolidated accounting period.」

「Neurovascular revenue was ¥800 million, up 126.3% year on year, setting a new record for a first-half period. Sales of the additional embolization coil model introduced in the previous fiscal year remained strong. Sales of the thrombectomy catheter increased substantially during the current interim consolidated accounting period, driven by the promotion of a small-diameter model with few competing products. The company also began selling stent retrievers as a new product, which began contributing to revenue during the current interim consolidated accounting period.」

「Neurovascular revenue increased approximately 4.7 times year on year. Sales of the Avenir embolization coil remained strong, partly due to the contribution of the additional model introduced in the second quarter. Sales of the Esperance thrombectomy catheter, launched in the first quarter, also progressed well, as the expansion of consignment facilities proceeded faster than expected.」

「Neurovascular revenue increased approximately 6.1 times year on year. Expansion in the neurovascular field is one of the company's medium-term priorities, and it plans to develop approximately 10 products over the next several years. Sales of the Avenir embolization coil remained strong, and the launch of the additional Avenir Pico (アベニア・ピコ) model in the second quarter further increased market penetration. In addition, sales of the Esperance thrombectomy catheter, launched in the first quarter, progressed substantially above plan on the back of favorable clinical evaluations.」

「Revenue from neurovascular products increased approximately 5.7 times year on year. The company has identified expansion in the neurovascular field as one of its medium-term priorities and plans to develop approximately 10 products over the next several years. In the first quarter, in addition to the Avenir embolization coil, for which full-scale sales began in the previous fiscal year, the company launched the Esperance (エスペランス) thrombectomy catheter. Both products received favorable evaluations in clinical practice, and sales progressed above plan.」

「The company has entered into a 10-year exclusive distribution agreement with Wallaby Medical, the supplier of Avenir, covering 11 neurovascular treatment devices, and plans to launch the new products successively from the fiscal year ending March 2024.」

「Avenir was initially sold only for the abdominal field, but after sales for the neurovascular field began in April 2022, the number of newly adopting facilities has increased. In August 2022, the company also entered into a 10-year exclusive distribution agreement with Wallaby Medical, Avenir's supplier, covering 11 neurovascular treatment devices, substantially expanding its product lineup. The new products are scheduled to be launched successively from the fiscal year ending March 2024.」

「In August 2022, the company also entered into a 10-year exclusive distribution agreement with Wallaby Medical covering 11 neurovascular treatment devices, substantially expanding its product lineup. The new products are scheduled to be launched successively from the fiscal year ending March 2024. With the neurovascular market expected to expand by approximately 4–5% annually, the company will focus on it as an important area going forward.」

「Sales of Avenir, the embolization coil launched in the previous fiscal year, exceeded plan. The product was initially sold only for the abdominal field, but sales for the neurovascular field began in April 2022. The company regards the neurovascular field as its next key business area and will focus on it by further expanding its product lineup.」

「The company began selling the Avenir (アベニア) endovascular embolization coil ahead of schedule in December 2021 in the abdominal field, where it had already established strengths. From April 2022, it also began sales in the neurovascular field. The company regards the neurovascular field as a new growth area and is working to develop the market.」